Jill Feldman: Updated living guidelines for treating stage IV NSCLC with driver alterations
Jill Feldman, Co-Founder EGFR Resisters and a member of the programmatic panel for the Department of Defense Lung Cancer, shared a post on X:
“The ASCO has released updated living guidelines for treating stage IV NSCLC with driver alterations!
Click here to check out the new recommendations.
With the rapidly evolving, complex treatment algorithms, this guideline is critical!
It was an honor to serve on this panel alongside exceptional experts who are all dedicated to providing the most up-to-date, evidence-based guidance to oncology professionals and patients.”
Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023